文献速递临床试验与 GCP流行病学与生物统计

高剂量ω-3脂肪酸对比玉米油对高心血管风险患者主要不良心血管事件的影响:STRENGTH随机临床试验

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

ω-3组胃肠道不良事件更多(24.7% vs 14.7%)。

要点

  • 他汀治疗的高心血管风险患者中,加用ω-3羧酸制剂4g/d未显著降低主要不良心血管事件。
  • ω-3组胃肠道不良事件发生率24.7%,高于玉米油组的14.7%。

核心结论

  • 在他汀治疗的高心血管风险患者中,与玉米油相比,加用ω-3羧酸制剂未显著减少主要不良心血管事件复合终点。
  • 研究结果不支持使用该ω-3脂肪酸制剂降低高危患者的主要不良心血管事件。

研究设计与样本

  • 双盲、随机、多中心试验,2014年10月30日至2017年6月14日入组,2020年1月8日终止,末次访视2020年5月14日。
  • 参与者随机接受ω-3羧酸制剂4g/d(n=6539)或玉米油(n=6539),并接受包括他汀在内的常规背景治疗。

主要发现

  • 当1384例患者发生主要终点事件(计划1600例)时,基于中期分析提示ω-3组对比玉米油组临床获益概率低,试验提前终止。
  • ω-3组胃肠道不良事件发生率24.7%,高于玉米油组的14.7%。

关键数值与推荐

  • 主要疗效终点为心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或需住院的不稳定心绞痛复合终点。
  • ω-3组胃肠道不良事件24.7% vs 玉米油组14.7%。

临床怎么用

  • 对于他汀治疗的高心血管风险患者,不应以降低主要不良心血管事件为目的加用该ω-3羧酸制剂4g/d。
  • 处方该ω-3制剂时需关注胃肠道不良事件风险。

局限性

  • 试验因中期分析提示获益概率低而提前终止,未达到计划的主要终点事件数。
  • 对照组使用玉米油,原文称其拟作为惰性对照,但玉米油可能并非完全惰性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk. OBJECTIVE: To determine the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial (enrollment October 30, 2014, to June 14, 2017; study termination January 8, 2020; last patient visit May 14, 2020) comparing omega-3 CA with corn oil in statin-treated participants with high cardiovascular risk, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C). A total of 13 078 patients were randomized at 675 academic and community hospitals in 22 countries in North America, Europe, South America, Asia, Australia, New Zealand, and South Africa. INTERVENTIONS: Participants were randomized to receive 4 g/d of omega-3 CA (n = 6539) or corn oil, which was intended to serve as an inert comparator (n = 6539), in addition to usual background therapies, including statins. MAIN OUTCOMES AND MEASURES: The primary efficacy measure was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. RESULTS: When 1384 patients had experienced a primary end point event (of a planned 1600 events), the trial was prematurely halted based on an interim analysis that indicated a low probability of clinical benefit of omega-3 CA vs the corn oil comparator. Among the 13 078 treated patients (mean [SD] age, 62.5 [9.0] years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholesterol level, 75.0 mg/dL; median triglycerides level, 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sensitivity C-reactive protein level, 2.1 mg/L), 12 633 (96.6%) completed the trial with ascertainment of primary end point status. The primary end point occurred in 785 patients (12.0%) treated with omega-3 CA vs 795 (12.2%) treated with corn oil (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A greater rate of gastrointestinal adverse events was observed in the omega-3 CA group (24.7%) compared with corn oil-treated patients (14.7%). CONCLUSIONS AND RELEVANCE: Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events. These findings do not support use of this omega-3 fatty acid formulation to reduce major adverse cardiovascular events in high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02104817.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020. PMID: 33190147. doi:10.1001/jama.2020.22258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。